Topical timolol maleate for the treatment of infantile hemangiomas works, but referral is still the standard of care
Metadata[+] Show full item record
Bottom line: Off-label use of timolol maleate was welltolerated, safe, and showed moderate to good effectiveness in patients with high-risk infantile hemangioma who had been referred to a specialist for treatment. Current standard of care in this situation is referral to a vascular anomaly specialist. This study does not change this practice.Review of: Puttgen K, Lucky A, Adams D, Pope E, McCuaig C, Powell J, et al; for the Hemangioma Investigator Group. Topical timolol maleate treatment of infantile hemangiomas. Pediatrics. 2016; 138(3). Epub 2016 Aug 15.
Evidence-based practice 20, no. 9 (2017): 6.